U.S. Markets closed

Veracyte, Inc. (VCYT)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
8.11+0.13 (+1.63%)
At close: 4:00PM EDT
People also watch
NSTGOXFDFMIVSTMKIN
Interactive chart
Previous Close7.98
Open7.93
Bid6.19 x 100
Ask8.50 x 200
Day's Range7.85 - 8.12
52 Week Range4.81 - 9.71
Volume50,431
Avg. Volume143,698
Market Cap274.69M
Beta2.00
PE Ratio (TTM)-8.34
EPS (TTM)-0.97
Earnings DateAug 1, 2017 - Aug 7, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.67
Trade prices are not sourced from all markets
  • PR Newswire3 days ago

    Veracyte Announces Clinical Validation Data Demonstrating Envisia™ Genomic Classifier's Performance in Improving Idiopathic Pulmonary Fibrosis Diagnosis Presented at ATS 2017

    SOUTH SAN FRANCISCO, Calif., May 23, 2017 /PRNewswire/ -- Veracyte, Inc. (VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, announced today that pivotal clinical validation data demonstrating the performance of its Envisia Genomic Classifier were presented at the American Thoracic Society 2017 International Conference (ATS 2017) being held in Washington, DC. At the ATS meeting today, investigators presented pivotal clinical validation study results confirming the Envisia classifier's ability to detect usual interstitial pneumonia (UIP), a pattern whose presence is essential to IPF diagnosis, without the need for surgery.

  • PR Newswire9 days ago

    Veracyte Announces Anthem Coverage for the Afirma® Gene Expression Classifier for Use in Thyroid Cancer Diagnosis

    SOUTH SAN FRANCISCO, Calif., May 18, 2017 /PRNewswire/ --  Veracyte, Inc. (VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, today announced that Anthem, Inc., an independent Blues plan and one of the nation's largest health benefits companies, has issued a positive coverage policy for Veracyte's Afirma Gene Expression Classifier (GEC) for use in thyroid cancer diagnosis. The policy renders the genomic test a medically necessary benefit for Anthem's approximately 40 million members, effective immediately.

  • PR Newswire16 days ago

    Data Demonstrating Cost-Effectiveness of Veracyte's Percepta® Bronchial Genomic Classifier Published in "Journal of Thoracic Oncology"

    SOUTH SAN FRANCISCO, Calif., May 11, 2017 /PRNewswire/ -- Veracyte, Inc. (VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, announced that data demonstrating the cost-effectiveness of the Percepta Bronchial Genomic Classifier were published for the first time today in the Journal of Thoracic Oncology (JTO). The Percepta classifier is used to resolve inconclusive bronchoscopy results in patients undergoing evaluation for potentially cancerous lung nodules or lesions. This frequently leads to patients undergoing potentially risky, expensive and unnecessary invasive procedures, including transthoracic needle biopsy (TTNB) and surgical lung biopsy (SLB), to obtain a more definitive diagnosis.